logo
School of Molecular Medical Sciences
   
   
  

Course Introduction

 

 Cancer Immunology and Biotechnology
 

The biggest modern breakthrough for cancer treatment has been antibody therapies. An increasing number of biotechnology companies have in development antibodies or vaccines based cancer therapies. This course aims to attract students interested in tumour immunology who wish to pursue a career either in industry (biotechnology) or academia.

The course covers both antibody and vaccine, cancer therapies and explores the immunology of the tumour host interface. In addition, students will learn about intellectual property and how to exploit scientific research in scientific writings, patents and in development of business plans applicable to the biotechnology industry. To gain practical experience in research students will carry out a research project in the field of tumour immunology.

 

Innovative features of the course:

  • The only MSc course based entirely on tumour immunology
  • Students undertake a substantial research project, during which time they acquire a considerable amount of laboratory-based skills
  • A module based entirely on scientific writing and the development of a business plan
  • Individuals from Industry lecture on the course
  • The course is suitable for graduates in Life Sciences, Biomedical Sciences and allied subjects and also for people already in suitable employment who wish to improve and update their knowledge and experience. The course attracts students from the UK and worldwide.
 

 

If you require further information, please refer to our Course Brochure

 

This course was previously known as the MSc in Cancer Immunotherapy.

 

 

School of Molecular Medical Sciences

Queen's Medical Centre
University of Nottingham
Nottingham NG7 2UH

telephone: +44 (0) 115 823 0771
fax: +44 (0) 115 823 0759
email: mol-enquiries@nottingham.ac.uk